TFEB and neurodegenerative disease: Given that TFEB activation mitigates toxic protein accumulation in neurodegenerative diseases such as Parkinson’s disease (PD) [29,30], we investigated whether KHS-101 reduces levels of A53T mutant α-synuclein, a key pathological hallmark of PD.